-
Sale
Vertex 250 mg/vialVertex 250 mg/vial is indicated for the treatment of the following major infections: Lower respiratory tract infections Acute Bacterial Otitis Media Skin and skin structure infections Urinary tract infections Gonorrhea Bacterial Septicemia Bone and joint infections Meningitis Prevention of postoperative infections Perioperative prophylaxis of infections associated with surgery Theropeutic ClassThird generation CephalosporinsPharmacologyVertex 250 mg/vial is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic. It has potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. Like other cephalosporins and penicillins, Vertex 250 mg/vial kills bacteria by interfering with the synthesis of the bacterial cell wall. Vertex 250 mg/vial has a high degree of stability in the presence of beta lactamases. A remarkable feature of Vertex 250 mg/vial is its relatively long plasma elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most patients. Vertex 250 mg/vial is not metabolized in the body. About 40-65% of a dose of Vertex 250 mg/vial is excreted unchanged in the urine; the remainder is excreted in the bile and ultimately found in the feces as unchanged drug and microbiologically inactive compound. The drug is highly protein bound (95%).Dosage of Vertex 250 mg/vialAdult: The usual dose is 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections, Meningitis: 1 to 2 g IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 4 gm/day Uncomplicated gonococcal infections: 250 mg IM as a single dose Surgical prophylaxis: 1 g IV as a single dose 30 to 120 minutes before surgery Infants and Children (01 month or older): The usual dose is 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections: 50 to 75 mg/kg IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 2 gm/day Acute bacterial otitis media: 50 mg/kg IM in single dose; Maximum dose: 1 gm/day Meningitis: 100 mg/kg IV or IM in single daily dose or (or in equally divided doses twice a day); Maximum dose: 4 gm/day Duration of therapy: Continue for more than 2 days after signs and symptoms of infection have disappeared. Usual duration is 4 to 14 days; in complicated infections, longer therapy may be required.Administration of Vertex 250 mg/vialPreparation of Solutions for Intramuscular / Intravenous Injections: For Intramuscular Injection: 250 mg or 500 mg Vertex 250 mg/vial should be dissolved in 2 ml Lidocaine HCI 1% injection or 1 g Vertex 250 mg/vial in 3.5 ml of Lidocaine HCI 1% injection. For Intravenous Injection: 250 mg or 500 mg Vertex 250 mg/vial should be dissolved in 5 ml of Water for injection or 1 g Vertex 250 mg/vial in 10 ml of Water for injection USP or 2 g Vertex 250 mg/vial in 20 ml of Water for injection. The injection should be administered over 2-4 minutes, by Intramuscular or Intravenous injection or by tubing infusion over a period of 30 minutes at concentration between 10 mg/mL and 40 mg/mL. Before starting treatment through Vertex 250 mg/vial injection, patient tolerance test should be checked by administration of a test dose. (The use of freshly reconstituted solution is recommended. However, it maintains potency for at least 6 hours at room temperature or 24 hours at 5?C).Interaction of Vertex 250 mg/vialNo drug interactions have been reported.ContraindicationsVertex 250 mg/vial should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.Side Effects of Vertex 250 mg/vialVertex 250 mg/vial is generally well tolerated. A few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of SGOT or SGPT, bilirubinemia; CNS reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. Local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes.Pregnancy & LactationIts safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Low concentrations of Vertex 250 mg/vial are excreted in human milk. Caution should be exercised when Vertex 250 mg/vial is administered to a lactating mother.Precautions & WarningsAs with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken. Anaphylactic shock requires immediate countermeasures such as intravenous epinephrine followed by a glucocorticoid. In rare cases, shadows suggesting sludge have been detected by sonograms of the gallbladder. This condition was reversible on discontinuation or completion of Vertex 250 mg/vial therapy. Even if such findings are associated with pain, conservative, nonsurgical management is recommended. During prolonged treatment the blood picture should be checked at regular intervals.Overdose Effects of Vertex 250 mg/vialThere is no specific antidote. Treatment of overdosage should be symptomatic.Storage ConditionsVial store in a cool, dry place (below 30? C), away from light & moisture. Keep out of the reach of children.Use In Special PopulationsVertex 250 mg/vial must not be given to neonates if the neonates is premature and newborn (up to 28 days of age).Vertex250 mg/vial
Original price was: ₦5,516.50.₦4,964.85Current price is: ₦4,964.85. -
SaleVertex 500 mg/vialVertex 500 mg/vial is indicated for the treatment of the following major infections: Lower respiratory tract infections Acute Bacterial Otitis Media Skin and skin structure infections Urinary tract infections Gonorrhea Bacterial Septicemia Bone and joint infections Meningitis Prevention of postoperative infections Perioperative prophylaxis of infections associated with surgery Theropeutic ClassThird generation CephalosporinsPharmacologyVertex 500 mg/vial is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic. It has potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. Like other cephalosporins and penicillins, Vertex 500 mg/vial kills bacteria by interfering with the synthesis of the bacterial cell wall. Vertex 500 mg/vial has a high degree of stability in the presence of beta lactamases. A remarkable feature of Vertex 500 mg/vial is its relatively long plasma elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most patients. Vertex 500 mg/vial is not metabolized in the body. About 40-65% of a dose of Vertex 500 mg/vial is excreted unchanged in the urine; the remainder is excreted in the bile and ultimately found in the feces as unchanged drug and microbiologically inactive compound. The drug is highly protein bound (95%).Dosage of Vertex 500 mg/vialAdult: The usual dose is 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections, Meningitis: 1 to 2 g IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 4 gm/day Uncomplicated gonococcal infections: 250 mg IM as a single dose Surgical prophylaxis: 1 g IV as a single dose 30 to 120 minutes before surgery Infants and Children (01 month or older): The usual dose is 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections: 50 to 75 mg/kg IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 2 gm/day Acute bacterial otitis media: 50 mg/kg IM in single dose; Maximum dose: 1 gm/day Meningitis: 100 mg/kg IV or IM in single daily dose or (or in equally divided doses twice a day); Maximum dose: 4 gm/day Duration of therapy: Continue for more than 2 days after signs and symptoms of infection have disappeared. Usual duration is 4 to 14 days; in complicated infections, longer therapy may be required.Administration of Vertex 500 mg/vialPreparation of Solutions for Intramuscular / Intravenous Injections: For Intramuscular Injection: 250 mg or 500 mg Vertex 500 mg/vial should be dissolved in 2 ml Lidocaine HCI 1% injection or 1 g Vertex 500 mg/vial in 3.5 ml of Lidocaine HCI 1% injection. For Intravenous Injection: 250 mg or 500 mg Vertex 500 mg/vial should be dissolved in 5 ml of Water for injection or 1 g Vertex 500 mg/vial in 10 ml of Water for injection USP or 2 g Vertex 500 mg/vial in 20 ml of Water for injection. The injection should be administered over 2-4 minutes, by Intramuscular or Intravenous injection or by tubing infusion over a period of 30 minutes at concentration between 10 mg/mL and 40 mg/mL. Before starting treatment through Vertex 500 mg/vial injection, patient tolerance test should be checked by administration of a test dose. (The use of freshly reconstituted solution is recommended. However, it maintains potency for at least 6 hours at room temperature or 24 hours at 5?C).Interaction of Vertex 500 mg/vialNo drug interactions have been reported.ContraindicationsVertex 500 mg/vial should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.Side Effects of Vertex 500 mg/vialVertex 500 mg/vial is generally well tolerated. A few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of SGOT or SGPT, bilirubinemia; CNS reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. Local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes.Pregnancy & LactationIts safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Low concentrations of Vertex 500 mg/vial are excreted in human milk. Caution should be exercised when Vertex 500 mg/vial is administered to a lactating mother.Precautions & WarningsAs with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken. Anaphylactic shock requires immediate countermeasures such as intravenous epinephrine followed by a glucocorticoid. In rare cases, shadows suggesting sludge have been detected by sonograms of the gallbladder. This condition was reversible on discontinuation or completion of Vertex 500 mg/vial therapy. Even if such findings are associated with pain, conservative, nonsurgical management is recommended. During prolonged treatment the blood picture should be checked at regular intervals.Overdose Effects of Vertex 500 mg/vialThere is no specific antidote. Treatment of overdosage should be symptomatic.Storage ConditionsVial store in a cool, dry place (below 30? C), away from light & moisture. Keep out of the reach of children.Use In Special PopulationsVertex 500 mg/vial must not be given to neonates if the neonates is premature and newborn (up to 28 days of age).
Vertex500 mg/vial
Original price was: ₦7,171.45.₦6,454.25Current price is: ₦6,454.25. -
SaleXclor 125 mg/5 mlCefaclor is indicated in the treatment of the following infections: Otitis media, Lower respiratory tract infections, including pneumonia, bronchitis and acute exacerbation of chronic bronchitis, Upper respiratory tract infections, including pharyngitis and tonsillitis, Urinary tract infections, including pyelonephritis and cystitis, Skin and soft tissue infections, SinusitisTheropeutic ClassSecond generation CephalosporinsPharmacologyCefaclor is a second generation cephalosporin antibiotic which has stability against b-lactamase inactivation and possesses a broad spectrum of activity. Cefaclor is active against the following organisms in vitro: Alpha and beta haemolytic Streptococci, Staphylococci; including coagulase-positive, coagulase negative and penicillinase-producing strains, Streptococcus pneumoniae, Streptococcus pyogenes (Group A b-haemolytic Streptococci), Branhamella catarrhalis, Escherichia coli, Proteus mirabilis, Klebsiella species Haemophilus influenzae, including ampicillin-resistant strains. Cefaclor is generally effective in the eradication of Streptococci from the nasopharynx.Dosage of Xclor 125 mg/5 mlAdult- Usual dose: 250 mg 8 hrly. Bronchitis & pneumonia: 250 mg tid. Sinusitis: 500 mg tid for 10 days. Pneumonia & other more severe infections: Max: 4 gm/day for 28 days. Acute gonococcal urethritis: 3 gm as a single dose combined with probenecid 1 gm. Children-? Recommended dose: 20 mg/kg/day in divided doses 8 hrly. Bronchitis & pneumonia: 20 mg/kg/day in divided doses tid. Serious infections, sinusitis, otitis media & infections: caused by less susceptible organisms 40 mg/kg/day in divided doses. Max: 1 gm/day. Administration of Xclor 125 mg/5 mlMay be taken with or without food.Interaction of Xclor 125 mg/5 mlThe nephrotoxicity of aminoglycoside antibiotics such as gentamicin and tobramicin may be enhanced by any cephalosporin. Therefore, one should be cautious in concomitant use of these categories of drugs.ContraindicationsCefaclor is contraindicated in patients with known allergy to the Cephalosporin group of antibiotics.Side Effects of Xclor 125 mg/5 mlGastro-intestinal: Diarrhoea, nausea and vomiting have been reported. Hypersensitivity: Allergic reactions such as eruptions, pruritis and urticaria have been observed. These reactions usually subside upon discontinuation of therapy. Serum sickness like reactions have been reported. Haematological: Eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. Hepatic: Transient hepatitis and cholestatic jaundice, slight elevation in AST, ALT or alkaline phosphate values have been reported rarely. Renal: Reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.Central Nervous System: Reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely.Pregnancy & LactationThere are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Small amounts of Cefaclor have been detected in mother's milk. The effect on nursing infants is not known. Caution should be exercised when Cefaclor is administered to a nursing woman.Precautions & WarningsCefaclor should be administered with caution in the presence of markedly impaired renal function. Dosage adjustments for patients with moderate or severe renal impairment are not usually required.Overdose Effects of Xclor 125 mg/5 mlSymptoms: Nausea, vomiting, epigastric distress and diarrhoea would be anticipated.Treatment: Unless 5 times the normal total daily dose has been ingested, gastrointestinal decontamination will not be necessary. General management may consist of supportive therapy.Storage ConditionsStore in a cool and dry place. Protect from light.Drug ClassesSecond generation CephalosporinsMode Of ActionCefaclor is a second generation cephalosporin antibiotic which has stability against b-lactamase inactivation and possesses a broad spectrum of activity. Cefaclor is active against the following organisms in vitro: Alpha and beta haemolytic Streptococci, Staphylococci; including coagulase-positive, coagulase negative and penicillinase-producing strains, Streptococcus pneumoniae, Streptococcus pyogenes (Group A b-haemolytic Streptococci), Branhamella catarrhalis, Escherichia coli, Proteus mirabilis, Klebsiella species Haemophilus influenzae, including ampicillin-resistant strains. Cefaclor is generally effective in the eradication of Streptococci from the nasopharynx.PregnancyThere are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Small amounts of Cefaclor have been detected in mother's milk. The effect on nursing infants is not known. Caution should be exercised when Cefaclor is administered to a nursing woman.
Xclor125 mg/5 ml
Original price was: ₦10,481.35.₦9,433.05Current price is: ₦9,433.05. -
SaleXemi 320 mgXemi 320 mg is indicated for the treatment of the following bacterial infections in adults caused by sensitive organisms as follows- Acute bacterial exacerbation of chronic bronchitis:?caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. ... Read moreXemi 320 mg is indicated for the treatment of the following bacterial infections in adults caused by sensitive organisms as follows- Acute bacterial exacerbation of chronic bronchitis:?caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Community-acquired pneumonia (of mild to moderate severity):?caused by Streptococcus pneumoniae (including multi-drug resistant strains), Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae. Theropeutic Class4-Quinolone preparationsPharmacologyXemi 320 mg is a fluoroquinolone antibiotic. It is bactericidal with minimum bactericidal concentrations. Xemi 320 mg acts by inhibiting DNA synthesis through inhibition of the bacterial type II topoisomerases, DNA gyrase, and/or topoisomerase IV (TOPO IV) which are both essential for bacterial growth.Xemi 320 mg is rapidly absorbed after oral administration. It is widely distributed throughout the body. Studies in healthy subjects showed that Xemi 320 mg is distributed rapidly into target tissues and body fluids such as the lung (epithelial lining fluid, alveolar macrophages, bronchial tissue) and nasal secretions. Following oral administration of Xemi 320 mg, approximately 36% and 61% of the dose is excreted in the urine and feces, respectively, as unchanged drug and metabolites. AUC values were generally only slightly higher (approx. 10%) in women than in men. No dose adjustment is required based on genderDosage & Administration of Xemi 320 mgAcute bacterial exacerbation of chronic bronchitis: 320 mg once daily for 5 days.Community-acquired pneumonia (Mild to moderate?severity): Due to known or suspected S. pneumoniae, H. influenzae, M. pneumoniae, or C. pneumoniae infection: One 320 mg tablet daily for 5 days. Due to known or suspected multi-drug resistant Streptococcus pneumoniae, K.pneumoniae, or M. catarrhalis infection: One 320 mg tablet daily for 7 days. Dosage of Xemi 320 mgAcute bacterial exacerbation of chronic bronchitis: 320 mg once daily for 5 days.Community-acquired pneumonia (Mild to moderate?severity): Due to known or suspected S. pneumoniae, H. influenzae, M. pneumoniae, or C. pneumoniae infection: One 320 mg tablet daily for 5 days. Due to known or suspected multi-drug resistant Streptococcus pneumoniae, K.pneumoniae, or M. catarrhalis infection: One 320 mg tablet daily for 7 days. Interaction of Xemi 320 mgXemi 320 mg absorption is significantly reduced when aluminium or magnesium containing antacids and iron salts are concomitantly administered. Xemi 320 mg should be taken at least 2 hours before or 3 hours after these agents. Xemi 320 mg should be taken at least 2 hours before sucralfate administration. No clinically significant interactions have been observed when Xemi 320 mg was co-administered with omeprazole theophylline, digoxin, warfarin and oral contraceptives.ContraindicationsKnown hypersensitivity to Xemi 320 mg and other quinolones, Patients who have previously suffered tendon damage with fluoroquinolones. Xemi 320 mg should not be used in children under 18 years of age.Side Effects of Xemi 320 mgThe general adverse events include abdominal pain, diarrhea, headache, nausea, rash and vomiting. Some side effects have been infrequently reported such as fungal overgrowth in body, dizziness and insomnia, urticaria, pruritis and a maculopapular erythmatous skin rash.Pregnancy & LactationXemi 320 mg should not be used in pregnant or lactating women. The safety and efficacy of Xemi 320 mg in pregnant or lactating women have not been established.Precautions & WarningsFor patients with severe impairment of renal function, alteration of the dosage regimen to 160 mg once daily is necessary. Adequate hydration of patients receiving Xemi 320 mg should be maintained to prevent the formation of a highly concentrated urine and crystalluria. Xemi 320 mg may cause dizziness; if this occurs, patients should not operate an automobile or machinery or engage in activities requiring mental alertness or co-ordination.Tendinitis and tendon ruptures may occur in any age group during treatment with quinolones, including Xemi 320 mg, but particularly in elderly patients or when corticosteroids are being co-administered. Xemi 320 mg should be discontinued if tendinitis is suspected or at the first sign of pain or inflammation and the affected limb should be rested. In clinical studies with Xemi 320 mg a small mean increase in QTc interval was observed. Xemi 320 mg should be used with caution in patients predisposed to QTc interval prolongation or in patients taking other medications that are known to prolong the QTc interval. Xemi 320 mg should be used with caution in patients with epilepsy.Overdose Effects of Xemi 320 mgNo specific antidote is known. Dialysis does not remove Xemi 320 mg sufficiently to be useful in overdose. In the event of acute oral overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage; the patient should be carefully observed, treated symptomatically and adequate hydration should be maintained.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Use In Special PopulationsRenal impairment:?Dose adjustment in patients with mild/moderate renal impairment is not required. Some modification of dosage is recommended for patients with severe renal dysfunction. The following table provides dosage guidelines for use in patients with renal impairment: Creatinine Clearance (>40 ml/min):??See usual dosage Creatinine Clearance (40 ml/min):??See usual dosage Creatinine Clearance (<40 ml/min): 160 mg once daily Patients on haemodialysis or continuous ambulatory peritoneal dialysis therapy should receive 160 mg once daily. Hepatic impairment:? Xemi 320 mg may be given to patients with hepatic impairment, with no?requirement for dose adjustment.Elderly patients: Dose adjustment is not required.
Xemi320 mg
Original price was: ₦2,758.25.₦2,482.70Current price is: ₦2,482.70. -
SaleXil 25 mgXil 25 mg is indicated for: Neuropathic pain linked to diabetic peripheral neuropathy is one condition for which Xil 25 mg is prescribed (DPN) Neuralgia following shingles (PHN) Treatment of partial-onset seizures in patients older than one month with adjunctive therapy Fibromyalgia neuropathic pain brought on by spinal cord damage. Neuropathic pain linked to diabetic peripheral neuropathy is one condition for which Xil 25 mg is prescribed (DPN) Neuralgia following shingles (PHN) Treatment of partial-onset seizures in patients older than one month with adjunctive therapy Fibromyalgia the neuropathic pain brought on by spinal cord damage The following conditions are treated with Xil 25 mg CR tablets: Neuropathic pain brought on by diabetic peripheral neuropathy (DPN) Neuralgia following shingles (PHN)Theropeutic ClassSupplemental antiepileptic medicationsPharmacologyGamma-amino butyric acid, an inhibitory neurotransmitter, is the structural basis of the drug Xil 25 mg (GABA). The GABAA, GABAB, or benzodiazepine receptors are not directly bound by it. In the tissues of the central nervous system, Xil 25 mg binds to the alpha-2-delta site (an auxiliary subunit of voltage-gated calcium channels) with a high affinity. Xil 25 mg has a 90% oral bioavailability that is dose-independent. In people with normal renal function, it is largely excreted from the body through the kidneys as an unaltered medication with a mean elimination half-life of 6.3 hours.Dosage & Administration of Xil 25 mgNeuropathic pain associated with diabetic peripheral neuropathy: The maximum recommended dose of Xil 25 mg is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability.Post-herpetic neuralgia: The recommended dose of Xil 25 mg is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 75 mg two times a day, or 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Adjunctive therapy for adult patients with partial onset seizures: In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Based on individual patient response and tolerability, the dose may be increased to a maximum dose of 600 mg/day.Management of Fibromyalgia: The recommended dose of Xil 25 mg for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.Neuropathic pain associated with spinal cord injury: The recommended dose range is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Xil 25 mg capsules can be taken without regards to meals.Dosage of Xil 25 mgNeuropathic pain associated with diabetic peripheral neuropathy in adults (DPN): The maximum recommended dose of Xil 25 mg is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Begin dosing of Xil 25 mg CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. The maximum recommended dose of Xil 25 mg CR capsule is 330 mg once daily.Postherpetic neuralgia in adults (PHN): The recommended dose of Xil 25 mg is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Xil 25 mg, may be treated with up to 300 mg two times a day or 200 mg three times a day (600 mg/day).Begin dosing of Xil 25 mg CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 330 mg once daily and who are able to tolerate Xil 25 mg CR capsule, may be treated with up to 660 mg once daily. In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, dosing above 330 mg/day should be reserved only for those patients who have on-going pain and are tolerating 330 mg daily. The maximum recommended dose of Xil 25 mg CR capsule is 660 mg once daily.Management of fibromyalgia in adults: The recommended dose of Xil 25 mg is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Xil 25 mg is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate Xil 25 mg may be treated with up to 300 mg two times a day. Conversion from Xil 25 mg capsules to Xil 25 mg CR capsule tablet: When switching from Xil 25 mg capsules to Xil 25 mg CR capsule tablet on the day of the switch, instruct patients to take their morning dose of Xil 25 mg capsule as prescribed and initiate Xil 25 mg CR capsule therapy after an evening meal.Xil 25 mg tablet total daily dose (dosed 2 or 3 times daily): Xil 25 mg CR capsule capsule dose (dosed once a day) 75 mg/daily: 82.5 mg/day 150 mg/daily: 165 mg/day 225 mg/daily: 247.5 mg/day 300 mg/daily: 330 mg/day 450 mg/daily: 495 mg/day 600 mg/daily: 660 mg/dayAdministration of Xil 25 mgRoute of administration: Xil 25 mg is administered orally. Taking it with or without food is acceptable. The Xil 25 mg CR tablet should be taken after dinner. It shouldn't be divided, crushed, or chewed; it should be consumed whole. Patients should take their regular dose of Xil 25 mg CR after a snack if they forget to take their evening mealtime dose of Xil 25 mg CR. If they forget to take Xil 25 mg CR before going to bed, they should take their regular dose of Xil 25 mg CR after breakfast. They should take their regular dose of Xil 25 mg CR at the regular time that evening after an evening meal if they forget to take their daily dose of Xil 25 mg CR after the morning meal.Interaction of Xil 25 mgDrug interaction with medication: There are not anticipated to be many significant pharmacokinetic medication interactions involving Xil 25 mg. No relevant drug-food or other-drug interactions.ContraindicationsThose with a known hypersensitivity to Xil 25 mg or any of its ingredients should not take Xil 25 mg.Side Effects of Xil 25 mgDizziness, somnolence, dry mouth, edema, impaired vision, weight gain, and aberrant thinking (mainly difficulties with concentration/attention) are the most frequent adverse effects in adults. Increased weight and increased hunger are the most frequent adverse reactions in children receiving therapy for partial-onset seizures.Pregnancy & LactationXil 25 mg is classified as a C pregnancy drug. Hence, it should only be used if the potential benefits outweigh the hazards to the fetus. Xil 25 mg should only be administered to nursing mothers if the risks are clearly outweighed by the potential benefits. Xil 25 mg may be released through breast milk like other medications.Precautions & WarningsAngioedema (swelling of the throat, head, and neck, for example) can happen and is sometimes linked to respiratory compromise that requires immediate medical attention. In these circumstances, Xil 25 mg should be stopped promptly. Also, if hypersensitivity reactions like hives, dyspnea, or wheezing manifest, Xil 25 mg should be stopped right away. Xil 25 mg and other antiepileptic medications raise the chance of having suicidal ideas or actions. Xil 25 mg may cause respiratory depression when used concurrently with CNS depressants or when there is underlying respiratory impairment. Patients must be watched closely, and dosage needs to be modified as necessary. Xil 25 mg may make a patient drowsy and woozy, making it difficult for them to drive or operate machinery. Xil 25 mg may become more frequent in seizures or have other negative effects if it is abruptly stopped. Xil 25 mg should be discontinued gradually over at least two weeks.Overdose Effects of Xil 25 mgReduced consciousness, melancholy or anxiety, confusional mood, agitation, and restlessness are signs and symptoms of a Xil 25 mg overdose. As well as heart block and seizures, there have been reports. There isn't a particular remedy. If necessary, emesis or stomach lavage may be used to try to eliminate any unabsorbed medication; normal safety procedures should be followed to preserve the airway. It is necessary to provide the patient with general supportive care, which includes keeping track of their vital signs and assessing their clinical condition.Storage ConditionsMaintain in a cool, dry location (below 30?C), away from light and moisture. Keep out of children's reach.Use In Special PopulationsXil 25 mg's efficacy and safety in pediatric patients have not been shown.Drug ClassesAdjunct anti-epileptic drugs, Primary anti-epileptic drugsMode Of ActionGamma-aminobutyric acid, an inhibitory neurotransmitter, is the structural basis of the drug Xil 25 mg (GABA). It doesn't directly bind to benzodiazepine, GABAA, or GABAB receptors. In the tissues of the central nervous system, Xil 25 mg binds to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) with a high affinity. Xil 25 mg's mechanism of action is still unknown, although findings from animal research point to a potential role for binding to the alpha2-delta subunit in the drug's anti-nociceptive and anti-seizure properties.PregnancyXil 25 mg use in expectant women has not been adequately and carefully studied. The potential harm to a fetus should be disclosed to expectant mothers. Xil 25 mg has been found in trace levels in the milk of nursing women. Breastfeeding is not advised while using Xil 25 mg due to the potential risk of tumorigenicity.Pediatric UsesUsage in children and adolescents: Safety and efficacy for the treatment of fibromyalgia, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, and neuropathic pain associated with diabetic peripheral neuropathy in pediatric patients have not been proven. The safety and efficacy of supplementary therapy for partial onset seizures in pediatric children younger than one month of age have not been established. Xil 25 mg extended-release tablet safety and efficacy in pediatric patients have not been shown.
Xil25 mg
Original price was: ₦550.00.₦495.00Current price is: ₦495.00. -
SaleXil 75 mgXil 75 mg is indicated for: Neuropathic pain linked to diabetic peripheral neuropathy is one condition for which Xil 75 mg is prescribed (DPN) Neuralgia following shingles (PHN) Treatment of partial-onset seizures in patients older than one month with adjunctive therapy Fibromyalgia neuropathic pain brought on by spinal cord damage. Neuropathic pain linked to diabetic peripheral neuropathy is one condition for which Xil 75 mg is prescribed (DPN) Neuralgia following shingles (PHN) Treatment of partial-onset seizures in patients older than one month with adjunctive therapy Fibromyalgia the neuropathic pain brought on by spinal cord damage The following conditions are treated with Xil 75 mg CR tablets: Neuropathic pain brought on by diabetic peripheral neuropathy (DPN) Neuralgia following shingles (PHN)Theropeutic ClassSupplemental antiepileptic medicationsPharmacologyGamma-amino butyric acid, an inhibitory neurotransmitter, is the structural basis of the drug Xil 75 mg (GABA). The GABAA, GABAB, or benzodiazepine receptors are not directly bound by it. In the tissues of the central nervous system, Xil 75 mg binds to the alpha-2-delta site (an auxiliary subunit of voltage-gated calcium channels) with a high affinity. Xil 75 mg has a 90% oral bioavailability that is dose-independent. In people with normal renal function, it is largely excreted from the body through the kidneys as an unaltered medication with a mean elimination half-life of 6.3 hours.Dosage & Administration of Xil 75 mgNeuropathic pain associated with diabetic peripheral neuropathy: The maximum recommended dose of Xil 75 mg is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability.Post-herpetic neuralgia: The recommended dose of Xil 75 mg is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 75 mg two times a day, or 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Adjunctive therapy for adult patients with partial onset seizures: In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Based on individual patient response and tolerability, the dose may be increased to a maximum dose of 600 mg/day.Management of Fibromyalgia: The recommended dose of Xil 75 mg for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.Neuropathic pain associated with spinal cord injury: The recommended dose range is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Xil 75 mg capsules can be taken without regards to meals.Dosage of Xil 75 mgNeuropathic pain associated with diabetic peripheral neuropathy in adults (DPN): The maximum recommended dose of Xil 75 mg is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Begin dosing of Xil 75 mg CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. The maximum recommended dose of Xil 75 mg CR capsule is 330 mg once daily.Postherpetic neuralgia in adults (PHN): The recommended dose of Xil 75 mg is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Xil 75 mg, may be treated with up to 300 mg two times a day or 200 mg three times a day (600 mg/day).Begin dosing of Xil 75 mg CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 330 mg once daily and who are able to tolerate Xil 75 mg CR capsule, may be treated with up to 660 mg once daily. In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, dosing above 330 mg/day should be reserved only for those patients who have on-going pain and are tolerating 330 mg daily. The maximum recommended dose of Xil 75 mg CR capsule is 660 mg once daily.Management of fibromyalgia in adults: The recommended dose of Xil 75 mg is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Xil 75 mg is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate Xil 75 mg may be treated with up to 300 mg two times a day. Conversion from Xil 75 mg capsules to Xil 75 mg CR capsule tablet: When switching from Xil 75 mg capsules to Xil 75 mg CR capsule tablet on the day of the switch, instruct patients to take their morning dose of Xil 75 mg capsule as prescribed and initiate Xil 75 mg CR capsule therapy after an evening meal.Xil 75 mg tablet total daily dose (dosed 2 or 3 times daily): Xil 75 mg CR capsule capsule dose (dosed once a day) 75 mg/daily: 82.5 mg/day 150 mg/daily: 165 mg/day 225 mg/daily: 247.5 mg/day 300 mg/daily: 330 mg/day 450 mg/daily: 495 mg/day 600 mg/daily: 660 mg/dayAdministration of Xil 75 mgRoute of administration: Xil 75 mg is administered orally. Taking it with or without food is acceptable. The Xil 75 mg CR tablet should be taken after dinner. It shouldn't be divided, crushed, or chewed; it should be consumed whole. Patients should take their regular dose of Xil 75 mg CR after a snack if they forget to take their evening mealtime dose of Xil 75 mg CR. If they forget to take Xil 75 mg CR before going to bed, they should take their regular dose of Xil 75 mg CR after breakfast. They should take their regular dose of Xil 75 mg CR at the regular time that evening after an evening meal if they forget to take their daily dose of Xil 75 mg CR after the morning meal.Interaction of Xil 75 mgDrug interaction with medication: There are not anticipated to be many significant pharmacokinetic medication interactions involving Xil 75 mg. No relevant drug-food or other-drug interactions.ContraindicationsThose with a known hypersensitivity to Xil 75 mg or any of its ingredients should not take Xil 75 mg.Side Effects of Xil 75 mgDizziness, somnolence, dry mouth, edema, impaired vision, weight gain, and aberrant thinking (mainly difficulties with concentration/attention) are the most frequent adverse effects in adults. Increased weight and increased hunger are the most frequent adverse reactions in children receiving therapy for partial-onset seizures.Pregnancy & LactationXil 75 mg is classified as a C pregnancy drug. Hence, it should only be used if the potential benefits outweigh the hazards to the fetus. Xil 75 mg should only be administered to nursing mothers if the risks are clearly outweighed by the potential benefits. Xil 75 mg may be released through breast milk like other medications.Precautions & WarningsAngioedema (swelling of the throat, head, and neck, for example) can happen and is sometimes linked to respiratory compromise that requires immediate medical attention. In these circumstances, Xil 75 mg should be stopped promptly. Also, if hypersensitivity reactions like hives, dyspnea, or wheezing manifest, Xil 75 mg should be stopped right away. Xil 75 mg and other antiepileptic medications raise the chance of having suicidal ideas or actions. Xil 75 mg may cause respiratory depression when used concurrently with CNS depressants or when there is underlying respiratory impairment. Patients must be watched closely, and dosage needs to be modified as necessary. Xil 75 mg may make a patient drowsy and woozy, making it difficult for them to drive or operate machinery. Xil 75 mg may become more frequent in seizures or have other negative effects if it is abruptly stopped. Xil 75 mg should be discontinued gradually over at least two weeks.Overdose Effects of Xil 75 mgReduced consciousness, melancholy or anxiety, confusional mood, agitation, and restlessness are signs and symptoms of a Xil 75 mg overdose. As well as heart block and seizures, there have been reports. There isn't a particular remedy. If necessary, emesis or stomach lavage may be used to try to eliminate any unabsorbed medication; normal safety procedures should be followed to preserve the airway. It is necessary to provide the patient with general supportive care, which includes keeping track of their vital signs and assessing their clinical condition.Storage ConditionsMaintain in a cool, dry location (below 30?C), away from light and moisture. Keep out of children's reach.Use In Special PopulationsXil 75 mg's efficacy and safety in pediatric patients have not been shown.Drug ClassesAdjunct anti-epileptic drugs, Primary anti-epileptic drugsMode Of ActionGamma-aminobutyric acid, an inhibitory neurotransmitter, is the structural basis of the drug Xil 75 mg (GABA). It doesn't directly bind to benzodiazepine, GABAA, or GABAB receptors. In the tissues of the central nervous system, Xil 75 mg binds to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) with a high affinity. Xil 75 mg's mechanism of action is still unknown, although findings from animal research point to a potential role for binding to the alpha2-delta subunit in the drug's anti-nociceptive and anti-seizure properties.PregnancyXil 75 mg use in expectant women has not been adequately and carefully studied. The potential harm to a fetus should be disclosed to expectant mothers. Xil 75 mg has been found in trace levels in the milk of nursing women. Breastfeeding is not advised while using Xil 75 mg due to the potential risk of tumorigenicity.Pediatric UsesUsage in children and adolescents: Safety and efficacy for the treatment of fibromyalgia, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, and neuropathic pain associated with diabetic peripheral neuropathy in pediatric patients have not been proven. The safety and efficacy of supplementary therapy for partial onset seizures in pediatric children younger than one month of age have not been established. Xil 75 mg extended-release tablet safety and efficacy in pediatric patients have not been shown.
Xil75 mg
Original price was: ₦882.75.₦794.75Current price is: ₦794.75. -
SaleXzema 2%+0.1%This cream is indicated for the treatment of eczematous dermatoses including atopic eczema, discoid eczema, stasis eczema and seborrhoeic eczema when secondary bacterial infection is confirmed or suspected.Theropeutic ClassBetamethasone & Combined preparationsPharmacologyBetamethasone is a topical fluorinated corticosteroid that has an anti-inflammatory and antipruritic effect. Fusidic acid is a potent topical antibacterial agent which is effective against Staphylococcus aureus, Streptococci, Corynebacteria, Neiserria and certain Clostridia and Bacteroides.Dosage & Administration of Xzema 2%+0.1%Apply this cream or ointment to the affected area twice daily. Max duration is 2 weeks.Interaction of Xzema 2%+0.1%Fucidic Acid: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.Betamethasone: Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or Gl bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum cone of salicylates and antimuscarinic agents.Potentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.ContraindicationsSkin lesions of viral, fungal or bacterial origin (e.g. herpes or varicella), skin manifestations in relation to TB or syphilis, perioral dermatitis and rosacea, ulcerative condition.Side Effects of Xzema 2%+0.1%Hypersensitivity, contact dermatitis, eczema (aggravated condition), skin burning sensation, pruritus, dry skin, application site pain or irritation. Rarely, erythema, urticaria (including rash erythematous and generalised rash), application site swelling or vesicles.Pregnancy & LactationTopical administration of any corticosteroid to pregnant animals can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively in pregnancy, i.e. in large amounts or for prolonged periodsPrecautions & WarningsMay increase risk of developing antibiotic resistance. Stasis dermatitis and other skin disease w/ impaired circulation. Not to be used for >7 days if there is no clinical improvement. Avoid prolonged continuous treatment esp in infants and children. Pregnancy and lactation.Storage ConditionsDo not store above 25? C. Store in original container.
Xzema2%+0.1%
Original price was: ₦11,074.25.₦9,966.55Current price is: ₦9,966.55. -
SaleZoana 100 mg/5 mlZoana 100 mg/5 ml is indicated for the treatment of diarrhea caused by Cryptosporidium parvum, Giardia lamblia and Entamoeba histolytica.Theropeutic ClassAnti-diarrhoeal AntiprotozoalPharmacologyZoana 100 mg/5 ml is a synthetic antiprotozoal agent for oral administration. The antiprotozoal activity of Zoana 100 mg/5 ml is believed to be interference with the Pyruvate Ferredoxin Oxido Reductase (PFOR) enzyme-dependant electron transfer reaction. This reaction is essential for anaerobic energy metabolism of the protozoa. Zoana 100 mg/5 ml and its metabolites, tizoxanid are active in vitro in inhibiting the growth of sporozoites and oocyst of Cryptosporidium parvum and trophozoites of Giardia lamblia.Dosage & Administration of Zoana 100 mg/5 mlAge 1-3 years: 1 tea-spoonfull or 5 ml suspension every 12 hours for 3 days. Age 4-11 years: 2 tea-spoonfulls or 10 ml suspension every 12 hours for 3 days.Age 12 years or above: 5 tea-spoonfulls (25 ml) suspension or 1 tablet every 12 hours for 3 days. It is recommended to be administered with food.Dosage of Zoana 100 mg/5 mlAge 1-3 years: 1 tea-spoonfull or 5 ml suspension every 12 hours for 3 days. Age 4-11 years: 2 tea-spoonfulls or 10 ml suspension every 12 hours for 3 days.Age 12 years or above: 5 tea-spoonfulls (25 ml) suspension or 1 tablet every 12 hours for 3 days. It is recommended to be administered with food.Interaction of Zoana 100 mg/5 mlIt is highly bound to plasma protein. Therefore, caution should be exercised when administering Zoana 100 mg/5 ml concurrently with other highly plasma protein-bound drugs with narrow therapeutic index.ContraindicationsIt is contraindicated in patients with known hypersensitivity to Zoana 100 mg/5 ml or any components of the preparation.Side Effects of Zoana 100 mg/5 mlThe most frequent side effects, reported by Zoana 100 mg/5 ml are abdominal pain, vomiting and headache. These side effects are typically mild and transient in nature. Very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine & SGPT level, pruritus, rhinitis, sweating, dizziness, discolored urine etc.Pregnancy & LactationUS FDA pregnancy category of Zoana 100 mg/5 ml is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Zoana 100 mg/5 ml have been shown to be excreted in human milk. So, caution should be exercised when Zoana 100 mg/5 ml is administered during lactation.Precautions & WarningsZoana 100 mg/5 ml must be administered with caution to patients with hepatic & biliary disease and to patients with renal disease.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Drug ClassesAnti-diarrhoeal AntiprotozoalMode Of ActionZoana 100 mg/5 ml is a synthetic antiprotozoal agent for oral administration. The antiprotozoal activity of Zoana 100 mg/5 ml is believed to be interference with the Pyruvate Ferredoxin Oxido Reductase (PFOR) enzyme-dependant electron transfer reaction. This reaction is essential for anaerobic energy metabolism of the protozoa. Zoana 100 mg/5 ml and its metabolites, tizoxanid are active in vitro in inhibiting the growth of sporozoites and oocyst of Cryptosporidium parvum and trophozoites of Giardia lamblia.PregnancyUS FDA pregnancy category of Zoana 100 mg/5 ml is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Zoana 100 mg/5 ml have been shown to be excreted in human milk. So, caution should be exercised when Zoana 100 mg/5 ml is administered during lactation.
Zoana100 mg/5 ml
Original price was: ₦1,938.75.₦1,745.15Current price is: ₦1,745.15. -
SaleZoana 500 mgZoana 500 mg is indicated for the treatment of diarrhea caused by Cryptosporidium parvum, Giardia lamblia and Entamoeba histolytica.Theropeutic ClassAnti-diarrhoeal AntiprotozoalPharmacologyZoana 500 mg is a synthetic antiprotozoal agent for oral administration. The antiprotozoal activity of Zoana 500 mg is believed to be interference with the Pyruvate Ferredoxin Oxido Reductase (PFOR) enzyme-dependant electron transfer reaction. This reaction is essential for anaerobic energy metabolism of the protozoa. Zoana 500 mg and its metabolites, tizoxanid are active in vitro in inhibiting the growth of sporozoites and oocyst of Cryptosporidium parvum and trophozoites of Giardia lamblia.Dosage & Administration of Zoana 500 mgAge 1-3 years: 1 tea-spoonfull or 5 ml suspension every 12 hours for 3 days. Age 4-11 years: 2 tea-spoonfulls or 10 ml suspension every 12 hours for 3 days.Age 12 years or above: 5 tea-spoonfulls (25 ml) suspension or 1 tablet every 12 hours for 3 days. It is recommended to be administered with food.Dosage of Zoana 500 mgAge 1-3 years: 1 tea-spoonfull or 5 ml suspension every 12 hours for 3 days. Age 4-11 years: 2 tea-spoonfulls or 10 ml suspension every 12 hours for 3 days.Age 12 years or above: 5 tea-spoonfulls (25 ml) suspension or 1 tablet every 12 hours for 3 days. It is recommended to be administered with food.Interaction of Zoana 500 mgIt is highly bound to plasma protein. Therefore, caution should be exercised when administering Zoana 500 mg concurrently with other highly plasma protein-bound drugs with narrow therapeutic index.ContraindicationsIt is contraindicated in patients with known hypersensitivity to Zoana 500 mg or any components of the preparation.Side Effects of Zoana 500 mgThe most frequent side effects, reported by Zoana 500 mg are abdominal pain, vomiting and headache. These side effects are typically mild and transient in nature. Very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine & SGPT level, pruritus, rhinitis, sweating, dizziness, discolored urine etc.Pregnancy & LactationUS FDA pregnancy category of Zoana 500 mg is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Zoana 500 mg have been shown to be excreted in human milk. So, caution should be exercised when Zoana 500 mg is administered during lactation.Precautions & WarningsZoana 500 mg must be administered with caution to patients with hepatic & biliary disease and to patients with renal disease.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Drug ClassesAnti-diarrhoeal AntiprotozoalMode Of ActionZoana 500 mg is a synthetic antiprotozoal agent for oral administration. The antiprotozoal activity of Zoana 500 mg is believed to be interference with the Pyruvate Ferredoxin Oxido Reductase (PFOR) enzyme-dependant electron transfer reaction. This reaction is essential for anaerobic energy metabolism of the protozoa. Zoana 500 mg and its metabolites, tizoxanid are active in vitro in inhibiting the growth of sporozoites and oocyst of Cryptosporidium parvum and trophozoites of Giardia lamblia.PregnancyUS FDA pregnancy category of Zoana 500 mg is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Zoana 500 mg have been shown to be excreted in human milk. So, caution should be exercised when Zoana 500 mg is administered during lactation.
Zoana500 mg
Original price was: ₦553.85.₦498.30Current price is: ₦498.30.
